Yıl: 2016 Cilt: 13 Sayı: 3 Sayfa Aralığı: 292 - 299 Metin Dili: İngilizce DOI: 10.4274/tjps.2016.02 İndeks Tarihi: 08-06-2020

Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study

Öz:
A simple, rapid and reliable high performance liquid chromatography method (HPLC) with ultraviolet detection (UV) was developed and validatedaccording to ICH guidelines, for quantitative analysis and therapeutic drug monitoring of diclofenac sodium (DS) in human plasma. Plasma samples (0.7mL) were acid hydrolysis by 100 µL, 1 M hydrochloric acid. Analytes were concentrated from plasma by liquid–liquid extraction with 2 mL ethyl acetateby repeated twice, which allows to obtain good extraction yields (98.75%-99.32%). The separation was achieved by employing C18 analytical column(3.5 µm particle size, 150 mmx3.9 mm I.D.) under isocratic conditions using acetonitrile and NaH2PO4 mixture (42.5:57.5, v/v) as mobile phase (pH:3.16) flow rate of 1.5 mL/min. Naproxen (3 µg/mL) was used as an internal standard (IS). The DS and IS were detected at 281 nm and eluted at 2.6 and6.2 min, respectively. Total run time was 7 min. Method showed linearity with very good determination coefficients (r2=0.999), over the concentrationrange of 50 - 1600 ng/mL. Limits of detection (LOD) and quantification (LOQ) were 8.95 ng/mL and 27.12 ng/mL, respectively. Intra-day precisionand accuracy were between 0.93-5.27; 1.74-9.81, respectively. Inter-day precision and accuracy were between 2.71-6.64; 2.03-9.16, respectively. Thismethod was successfully applied for determination of DS plasma concentrations during a pharmacokinetic study in healthy volunteers (n=12) after anoral administration of Voltaren® 75 mg/tablet and remarkable variations in DS levels were observed. In our study, on the contrary to equivalent dosesof DS, the observed significant differences in plasma levels of DS, on 2nd, 4th and 6th hours, can be explained by pharmacokinetic differences, that arisefrom mainly polymorphisms of CYP2C9 and CYP3A4, which are major enzymes responsible for DS metabolism.
Anahtar Kelime:

Diklofenak’ın İnsan Plazmasından HPLC-UV ile Tayin Yöntemi Geliştirilmesi ve Validasyonu ile Farmakokinetik Çalışmaya Uygulanması

Öz:
Diklofenak sodyumun (DS) insan plazmasında kantitatif analizleri ve terapötik ilaç izlemi için, basit, hızlı ve güvenilir bir ultraviyole dedektörlü yüksek performanslı sıvı kromatografisi (YPSK-UV) metodu geliştirildi ve ICH kurallarına göre valide edildi. Plazma örnekleri (0.7 mL) 100 µL, 1 M hidroklorik asitle hidroliz edildi. Analitler plazmadan iyi ekstraksiyon verimi (%98.75-%99.32) sağlayan sıvı-sıvı ekstraksiyonu metodu ile 2 mL etil asetatla iki tekrar ile elde edildi. Ayrım izokratik şartlar altında C18 analitik kolon (3.5 µm partikül büyüklüğü, 150 mmx3.9 mm I.D.), mobil faz asetonitril ve NaH2PO4 (42.5:57.5, v/v) karışımı (pH 3.16), akış hızı 1.5 mL/dk ile gerçekleştirildi. Naproksen (3 µg/mL) iç standart (İS) olarak kullanıldı. DS ve İS 281 nm’de ve sırasıyla 2.6 ve 6.2 dakikalarda tespit edildi. Toplam analiz süresi 7 dakika idi. Metot 50 - 1600 ng/mL konsantrasyon aralığında çok iyi bir belirlenme katsayısı ile (r2=0.999) doğrusallık gösterdi. Gözlenebilme sınırı ve tayin sınırı sırasıyla 8.95 ng/mL ve 27.12 ng/mL idi. Gün içi kesinlik ve doğruluk sırasıyla 0.93-5.27; 1.74-9.81 aralığında idi. Günler arası kesinlik ve doğruluk ise sırasıyla 2.71-6.64; 2.03-9.16 aralığında idi. Bu metot sağlıklı gönüllülerin (n=12) tek doz oral Voltaren® 75 mg/tablet alımı ile farmakokinetik çalışma süresince DS plazma konsantrasyonlarının belirlenmesi için başarıyla uygulandı ve DS düzeylerinde dikkate değer varyasyonlar gözlendi. Çalışmamızda DS’nin eşit dozlarına karşın, 2., 4. ve 6. saatlerdeki plazma düzeylerinde gözlenen anlamlı farklılıklar, özellikle DS metabolizmasından sorumlu majör enzimler olan CYP2C9 ve CYP3A4 polimorfizmlerinden kaynaklanabilecek farmakokinetik farklılıklarla açıklanabilir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Emara LH, Taha NF, El-Ashmawy AA, Raslan HM, Mursi NM. A rapid and sensitive bioanalytical hplc method for determining diclofenac sodium in human plasma for bioequivalence studies. J Liq Chromatogr Related Technol 35, 2203-2216, 2012.
  • 2. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Clin Pharmacokinet 3, 184-213, 1997.
  • 3. Menasse R, Hedwall PR, Kraetz J, Pesicinand C, Riesterer L. Pharmacological properties of diclofenac sodium and its metabolites. J Rheumatol Suppl 22, 5-16, 1978.
  • 4. Maier R, Menasse R, Riesterer L, Pericinand C, Ruegg M. The pharmacology of diclofenac sodium (Voltarol). Rheumatol Rehab Suppl 2, 11-21, 1979.
  • 5. Hassan SS, Yunus SH, Latif A. Study and improvement of methods for the determination of diclofenac sodium in pharmaceutical preparations. Pak J Pharm Sci 20-23, 7-10, 2010.
  • 6. Metabolism of Drugs and Other Xenobiotics. P. Anzenbacher and U.M. Zanger. pp. 408, Wiley-VCH, Weinheim, 2012.
  • 7. Dorado P, Berecz R, Caceres MC, LLerena A. Analysis of diclofenac and its metabolites by high-performance liquid chromatography: relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios. J Chromatogr B 789, 437–442, 2003.
  • 8. Ouellette GS, Slitzky BE, Gates JA, Lagardeand S, West AB. Reversible hepatitis associated with diclofenac. J Clin Gastroenterol 13, 205- 210, 1991.
  • 9. Banks AT, Zimmerman HJ, Ishakand KG, Harter JG. Diclofenacassociated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions. Hepatol 22, 820-827, 1995.
  • 10. Breen EG, McNicholl J, Cosgrove E, McCabeand J, Stevens FM. Fatal hepatitis associated with diclofenac. Gut 27, 1390-1393, 1986.
  • 11. Schapira D, Bassan L, Nahirand AM, Scharf Y. Diclofenac-induced hepatotoxicity. Postgrad Med J 62, 63-65, 1986.
  • 12. Dunk AA, Walt RP, Jenkinsand WJ, Sherlock SS. Diclofenac hepatisis. Br Med J (Clin Res Ed) 284, 1605-1606, 1982.
  • 13. Iveson TJ, Ryley NG, Kelly PM, Trowell JM, McGeeand JO, Chapman RW. Diclofenac associated hepatitis. J Hepatol 10, 85-89, 1990.
  • 14. Boelsterli UA, Zimmerman HJ, Kretz-Rommel A. Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: Molecular mechanisms and pathology. Crit Rev Toxicol 25, 207-235, 1995.
  • 15. Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerichand FP, Shimada T. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its cys- and leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 56, 243-251, 1998.
  • 16. Omura T, Sato R. The Carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239, 2379-2385, 1964.
  • 17. Davies NM, Anderson KE. Clinical Pharmacokinetics of Naproxen. Drug Disposition. 32, 268-293,1997
  • 18. Micalizzi YC, Pappano NB, Debattista NB. First and second order derivative spectrophotometric determination of benzyl alcohol and diclofenac in pharmaceutical forms. Talanta 47, 525-530, 1998.
  • 19. Kustrin A, Zivanovic L, Zecevic M, Radulovic D. Spectrophotometric study of diclofenac-Fe(III) complex. J Pharm Biomed 16, 147-153, 1997.
  • 20. Kubo H, Umiguchi Y, Kinoshita T. Fluorometric determination of methotrexate in serum by high performance liquid chromatography using in-line oxidation with hydrogen peroxide. J Liq Chromatogr 16, 465-474, 1993.
  • 21. Carreira L.A, Rizk M, El-Shabrawy M, Zakhari NA, Toubar S. Europium (III) ion probe spectrofluorometric determination of diclofenac sodium. J Pharm Biomed 13, 1331-1337, 1995.
  • 22. Ali A.M.M. Cathodic adsorptive stripping voltammetric determination of the anti-inflammatory drug indomethacin. J Pharm Biomed Anal 18, 1005-1012, 1999.
  • 23. Aly F, Belal F. Conductimetric determination of some nonsteroidal anti-inflammatory drugs in dosage forms. Pharmazie 49, 454-455, 1994.
  • 24. Martin MJ, Pablos F, Gonzalez AG. Simultaneous determination of caffeine and non-steroidal anti-inflammatory drugs in pharmaceutical formulations and blood plasma by reversed-phase HPLC from linear gradient elution. Talanta 49, 453-459, 1999.
  • 25. Haque A, Stewart JT. Direct injection HPLC analysis of some nonsteroidal antiinfammatory drugs on restricted access media columns. Chromatogr 13, 51-56, 1999.
  • 26. Yilmaz B, Asci A, Palabiyik SS. HPLC method for determination of diclofenac in human plasma and its application to a pharmacokinetic study in Turkey. J Chromatogr Sci. 49, 422-427, 2011.
  • 27. Arcelloni C, Lanzi R, Pedercini S, Molteni G, Fermo I, Pontiroli A, Paroni R. High-performance liquid chromatographic determination of diclofenac in human plasma after solid-phase extraction. J Chromatogr B, 763, 195-200, 2001
  • 28. Lee HS, Jeong CK, Choi SJ, Kim SB, Lee MH, Ko GI, Sohn DH. Simultaneous determination of aceclofenac and diclofenac in human plasma by narrowbore HPLC using column-switching. J Pharm Biomed Anal, 23, 775–781, 2000.
  • 29. Chawla JL, Sodhi RA, Sane RT. Simultaneous determination of chlorzoxazone, paracetamol and diclofenac sodium by different chromatographic techniques. Indian Drugs 33, 171-178, 1996.
  • 30. Leis HJ, Auler GF, Gleispach H, Windischofer W. Preparation of deuterated diclofenac for use as an internal standard in quantitative measurement by gas chromatography negative-ion chemical ionization mass spectrometry. Rapid Commun Mass Spectrom 10, 1605–1606, 1996.
  • 31. Borenstein MR, Xue Y, Cooper S, Tzeng TB. Sensitive capillary gas chromatographic-mass spectrometric-selected-ion monitoring method for the determination of diclofenac concentrations in human plasma. J Chromatogr B Biomed Appl 11, 59-66, 1996.
  • 32. Donato MG, Baeyens W, Van-den-Bossche W, Sandra P. The determination of non-steroidal antiinflammatory drugs in pharmaceuticals by capillary zone electrophoresis and micellar electrokinetic capillary chromatography. J Pharm Biomed 12, 21-26, 1994.
  • 33. International Conference on Harmonization (ICH). Guidance for Industry Q2B Validation of analytical procedures: Methodology. November 1996.
  • 34. International Conference on Harmonization (ICH). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Validation of Analytical Procedures: Text And Methodology Q2(R1). November 2005.
  • 35. Lala LG, D’Mello PM, Naile SR. J. HPT LC determination of diclofenac sodium from serum. Pharmaceut Biomed 29, 539-544, 2002.
  • 36. Choi MH, Choi YK. Rapid and sensitive analysis of diclofenac in human plasma by GC/SIM/MS. Anal Lett 32, 2245-2253, 1999.
APA GÜL ARISOY G, Dural E, MERGEN G, ARISOY M, Güvendik G, Soylemezoglu T (2016). Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study. , 292 - 299. 10.4274/tjps.2016.02
Chicago GÜL ARISOY Gülsüm,Dural Emrah,MERGEN Görkem,ARISOY Mustafa,Güvendik Gülin,Soylemezoglu Tulin Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study. (2016): 292 - 299. 10.4274/tjps.2016.02
MLA GÜL ARISOY Gülsüm,Dural Emrah,MERGEN Görkem,ARISOY Mustafa,Güvendik Gülin,Soylemezoglu Tulin Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study. , 2016, ss.292 - 299. 10.4274/tjps.2016.02
AMA GÜL ARISOY G,Dural E,MERGEN G,ARISOY M,Güvendik G,Soylemezoglu T Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study. . 2016; 292 - 299. 10.4274/tjps.2016.02
Vancouver GÜL ARISOY G,Dural E,MERGEN G,ARISOY M,Güvendik G,Soylemezoglu T Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study. . 2016; 292 - 299. 10.4274/tjps.2016.02
IEEE GÜL ARISOY G,Dural E,MERGEN G,ARISOY M,Güvendik G,Soylemezoglu T "Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study." , ss.292 - 299, 2016. 10.4274/tjps.2016.02
ISNAD GÜL ARISOY, Gülsüm vd. "Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study". (2016), 292-299. https://doi.org/10.4274/tjps.2016.02
APA GÜL ARISOY G, Dural E, MERGEN G, ARISOY M, Güvendik G, Soylemezoglu T (2016). Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study. Turkish Journal of Pharmaceutical Sciences, 13(3), 292 - 299. 10.4274/tjps.2016.02
Chicago GÜL ARISOY Gülsüm,Dural Emrah,MERGEN Görkem,ARISOY Mustafa,Güvendik Gülin,Soylemezoglu Tulin Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study. Turkish Journal of Pharmaceutical Sciences 13, no.3 (2016): 292 - 299. 10.4274/tjps.2016.02
MLA GÜL ARISOY Gülsüm,Dural Emrah,MERGEN Görkem,ARISOY Mustafa,Güvendik Gülin,Soylemezoglu Tulin Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study. Turkish Journal of Pharmaceutical Sciences, vol.13, no.3, 2016, ss.292 - 299. 10.4274/tjps.2016.02
AMA GÜL ARISOY G,Dural E,MERGEN G,ARISOY M,Güvendik G,Soylemezoglu T Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study. Turkish Journal of Pharmaceutical Sciences. 2016; 13(3): 292 - 299. 10.4274/tjps.2016.02
Vancouver GÜL ARISOY G,Dural E,MERGEN G,ARISOY M,Güvendik G,Soylemezoglu T Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study. Turkish Journal of Pharmaceutical Sciences. 2016; 13(3): 292 - 299. 10.4274/tjps.2016.02
IEEE GÜL ARISOY G,Dural E,MERGEN G,ARISOY M,Güvendik G,Soylemezoglu T "Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study." Turkish Journal of Pharmaceutical Sciences, 13, ss.292 - 299, 2016. 10.4274/tjps.2016.02
ISNAD GÜL ARISOY, Gülsüm vd. "Development and Validation of HPLC-UV Method for the Determination of Diclofenac in Human Plasma with Application to a Pharmacokinetic Study". Turkish Journal of Pharmaceutical Sciences 13/3 (2016), 292-299. https://doi.org/10.4274/tjps.2016.02